Business

Jazz Pharmaceuticals

Advertisement

The maker of the narcolepsy medicine Xyrem rose on its deal to buy EUSA Pharma Inc. for $650 million to diversify its drug holdings, including a therapy for leukemia. Acquiring closely held EUSA, based in Langhorne, Pa., will immediately add to earnings, Dublin-based Jazz said, and increase 2013 revenue by $210 million to $230 million. EUSA posted first-quarter net sales of $46 million.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
We hope you've enjoyed your free articles.
Continue reading by subscribing to Globe.com for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com